{"gene":"CXCR4","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":1996,"finding":"SDF-1 (CXCL12) is the natural ligand for CXCR4 (LESTR/fusin); SDF-1 signals through CXCR4 to induce intracellular Ca2+ increase and chemotaxis in CXCR4-transfected cells, and blocks T-tropic HIV-1 infection of CD4+ cells expressing CXCR4.","method":"Receptor transfection assays, Ca2+ mobilization assay, chemotaxis assay, HIV-1 infection inhibition assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — two independent papers replicated in the same issue using transfection, functional calcium assay, chemotaxis, and viral infection assays","pmids":["8752280","8752281"],"is_preprint":false},{"year":1994,"finding":"CXCR4 (LESTR) was cloned as a novel seven-transmembrane, GTP-binding protein-coupled receptor highly expressed in leukocytes; transfected cells expressing LESTR did not bind IL-8, NPY, or a panel of other chemotactic ligands, leaving its natural ligand unidentified at that time.","method":"cDNA cloning from monocyte library, radiolabeled ligand binding assays, RT-PCR expression profiling","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — initial molecular cloning with binding assays; negative ligand identification result is mechanistically informative; single lab","pmids":["8276799"],"is_preprint":false},{"year":1998,"finding":"CXCR4-knockout mice exhibit haematopoietic and cardiac defects identical to those of SDF-1-deficient mice, indicating CXCR4 is the sole receptor for SDF-1 in vivo; CXCR4 loss also causes cerebellar granule cell migration defects, establishing CXCR4 as required for neuronal cell migration and patterning.","method":"Genetic knockout mouse model, phenotypic analysis of haematopoiesis, cardiac development, and cerebellar development","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function mouse model with specific cellular phenotypes; replicated against SDF-1 KO phenotype as epistatic control","pmids":["9634238"],"is_preprint":false},{"year":1996,"finding":"Primary syncytium-inducing HIV-1 strains are dual-tropic and can use either CXCR4 (LESTR/fusin) or CCR5 as co-receptors for entry into CD4+ cells.","method":"Infection assays using cat CCC/CD4 cells transiently expressing LESTR or CCR5","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct viral infection assay in receptor-transfected cells; single lab but clear functional readout","pmids":["8970955"],"is_preprint":false},{"year":1999,"finding":"SDF-1 requires the CXCR4 N-terminus for binding and activates downstream signaling through the second extracellular loop; activation requires the Asp-Arg-Tyr motif in the second intracellular loop and is pertussis-toxin sensitive (Gi-coupled). The C-terminal tail is dispensable for signaling. Several CXCR4 mutants unable to bind SDF-1 or signal still support HIV-1 infection, indicating that coreceptor function is independent of chemokine signaling.","method":"CXCR4 chimeras and point mutants, SDF-1 binding assays, calcium signaling assays, HIV-1 infection assays, pertussis toxin treatment","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis of defined domains with multiple functional readouts (binding, signaling, viral entry) in a single systematic study","pmids":["10074122"],"is_preprint":false},{"year":1998,"finding":"CXCR4 endocytosis is mediated by two distinct signals: a C-terminal serine-rich domain is required for ligand-induced but not phorbol ester-induced internalization, while a Ser/IleLeu motif mediates phorbol ester-induced but not ligand-induced endocytosis.","method":"CXCR4 deletion/mutation constructs, internalization assays in T cells, phorbol ester and SDF-1 stimulation","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis dissecting two independent endocytic pathways with clear functional readouts; single lab, multiple orthogonal conditions","pmids":["9718374"],"is_preprint":false},{"year":2001,"finding":"CXCR4 exists in antigenically distinct conformational states on primary T and B cells; conformational heterogeneity is not due to glycosylation, sulfation of the N-terminal domain, or pertussis toxin-sensitive G-protein coupling. The commonly used anti-CXCR4 antibody 12G5 recognizes only a subpopulation of CXCR4 molecules on primary cells.","method":"Monoclonal antibody panel, flow cytometry, chemotaxis assay, HIV-1 infection inhibition, pertussis toxin treatment, glycosylation and sulfation analysis","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple MAbs and orthogonal functional assays; single lab","pmids":["11533159"],"is_preprint":false},{"year":2002,"finding":"CXCR4 activation by SDF-1 (CXCL12) in glioma cells induces rapid phosphorylation of MAP kinases (ERK) and Akt (PKB), and protects glioma cells from serum withdrawal-induced apoptosis; CXCR4 also mediates glioma cell chemotaxis.","method":"Western blotting for ERK and Akt phosphorylation, apoptosis assay (serum withdrawal), Boyden chamber chemotaxis assay, receptor expression profiling across 16 glioma lines","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays (survival, ERK, Akt, chemotaxis) in multiple glioma lines; single lab","pmids":["12388552"],"is_preprint":false},{"year":2006,"finding":"CXCR4 physically associates with the T cell receptor (TCR) upon SDF-1α stimulation, and utilizes ITAM domains of the TCR to activate ZAP-70 tyrosine kinase, leading to prolonged ERK MAP kinase activation, increased intracellular calcium, robust AP-1 transcriptional activity, and SDF-1α costimulation of cytokine secretion in T cells.","method":"Co-immunoprecipitation of CXCR4 and TCR, ZAP-70 kinase assays, ERK phosphorylation assays, calcium flux assays, AP-1 reporter assay, cytokine secretion assay","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP plus multiple orthogonal functional readouts (kinase activity, calcium, transcription, cytokine) in a single study; single lab","pmids":["16919488"],"is_preprint":false},{"year":2009,"finding":"CXCR7 constitutively heterodimerizes with CXCR4 as efficiently as homodimerization; CXCR7 expression induces conformational rearrangements within preassembled CXCR4/Gαi protein complexes and impairs CXCR4-promoted Gαi-protein activation and calcium responses to CXCL12.","method":"BRET/energy transfer dimerization assays, G protein activation assays, calcium mobilization assays, primary T cell chemotaxis with CXCR4 pharmacological blockade","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — energy transfer assays plus functional signaling readouts (Gi activation, calcium, chemotaxis) in both transfected and primary cells; single lab","pmids":["19380869"],"is_preprint":false},{"year":2009,"finding":"CD74 forms functional heteromeric complexes with CXCR4 at the cell surface; these CD74/CXCR4 complexes mediate MIF-specific AKT activation that is blocked by anti-CXCR4 antibodies and AMD3100, while CXCL12-stimulated AKT activation is not reduced by anti-CD74.","method":"Co-immunoprecipitation from HEK293 cells and from primary monocytes, AKT phosphorylation assays, antibody/inhibitor blocking experiments","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP in transfected and primary cells plus functional signaling assay; single lab","pmids":["19665027"],"is_preprint":false},{"year":2011,"finding":"CXCR4 and CXCR7 have distinct roles in cortical interneuron migration: CXCR4 loss leads to interneuron motility defects and altered leading process morphology, and in vivo inhibition of Gαi/o signaling phenocopies Cxcr4-knockout lamination defects, whereas CXCL12 stimulation of CXCR7 (but not CXCR4) promotes MAP kinase signaling.","method":"Cxcr4-/- and Cxcr7-/- knockout mice, live imaging of migrating interneurons, pharmacological CXCR4 blockade, in vivo pertussis toxin-mediated Gαi/o inhibition, MAPK signaling assays","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic knockouts, live imaging, pharmacological tools, and signaling assays across multiple orthogonal approaches; single lab but highly rigorous","pmids":["21220099"],"is_preprint":false},{"year":2005,"finding":"WHIM syndrome mutations in CXCR4 truncate the cytoplasmic tail, impairing receptor downregulation/desensitization and causing enhanced (gain-of-function) chemotaxis in response to CXCL12, establishing that CXCR4 C-tail truncation leads to aberrant prolonged signaling.","method":"Analysis of patient-derived CXCR4 mutations, chemotaxis assays with mutant receptor, biochemical studies of receptor desensitization","journal":"Immunological reviews","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional chemotaxis assays with mutant receptors in patient-derived and transfected cell contexts; reviewed finding corroborated by multiple studies","pmids":["15661033"],"is_preprint":false},{"year":2016,"finding":"Fine-tuning of CXCR4 desensitization is required for efficient plasma cell (PC) differentiation, trafficking, and bone marrow maintenance; a gain-of-function CXCR4 knockin mutation (phenocopying WHIM syndrome) intrinsically promotes germinal center response and PC differentiation but prevents antigen-specific PCs from homing to bone marrow survival niches, correlating with early accumulation of immature plasmablasts.","method":"WHIM syndrome knockin mouse model, immunization experiments, flow cytometry, antibody titer measurement, bone marrow analysis","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — knockin mouse model with specific cellular and functional phenotypes across multiple readouts; single lab","pmids":["27681431"],"is_preprint":false},{"year":2006,"finding":"HGF upregulates CXCR4 transcription in MCF-7 breast cancer cells via Ets1 (activated by MAPK1/ERK1/2) and NF-κB cooperating at the CXCR4 promoter; blocking these transcription factors with dominant negatives or inhibitors prevented CXCR4 induction and CXCL12-directed chemoinvasion. Hypoxia upregulates CXCR4 via HIF-1 and NF-κB.","method":"Dominant negative transcription factor constructs, pharmacological inhibitors, CXCR4 promoter-reporter assay, Boyden chamber chemoinvasion assay, Western blotting","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter-reporter, dominant negatives, and functional invasion assay; single lab, multiple orthogonal methods","pmids":["16840440"],"is_preprint":false},{"year":2008,"finding":"CXCR4-MIF (macrophage migration inhibitory factor) complexes occur in vivo in rat bladder urothelium and are detected by co-immunoprecipitation; cyclophosphamide-induced cystitis increases CXCR4 expression and CXCR4-MIF associations, and MIF-stimulated signaling through CXCR4 represents an alternative, non-cognate ligand pathway distinct from SDF-1/CXCR4 signaling.","method":"Co-immunoprecipitation from bladder tissue, immunohistochemistry, Western blotting, ELISA, real-time RT-PCR","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP from tissue in vivo plus multiple corroborating assays; single lab","pmids":["19066630"],"is_preprint":false},{"year":2014,"finding":"In kidney fibrosis (unilateral ureteral obstruction model), CXCR4 expression is upregulated in tubular cells and correlates with increased TGF-β1, PDGF-α, and decreased BMP7; genetic ablation of CXCR4 from tubular cells or macrophages attenuates fibrosis, Smad activation, and α-smooth muscle actin levels, revealing a CXCR4–TGF-β1–BMP7 pathway cross-talk in renal fibrosis.","method":"Cell-type-specific CXCR4 genetic knockout, unilateral ureteral obstruction model, Western blotting for TGF-β1/PDGF-α/BMP7/Smad/α-SMA, histology","journal":"American journal of physiology. Renal physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific knockouts with defined molecular pathway readouts; single lab","pmids":["25537742"],"is_preprint":false},{"year":2019,"finding":"PKC and GRK6 contribute to CXCR4 lysosomal trafficking and degradation via distinct mechanisms: PKC (activated heterologously by CXCR5/CXCL13 or phorbol ester) phosphorylates serine residues in the CXCR4 C-tail required for AIP4 (E3 ubiquitin ligase) binding and ubiquitination; GRK6 depletion by siRNA reduces CXCR4 degradation and ubiquitination. PKC inhibition does not alter CXCL12-mediated ubiquitination, indicating that GRK6 acts through a separate mechanism.","method":"PKC activation by phorbol ester (PMA) and heterologous CXCR5/CXCL13 stimulation, siRNA depletion of GRK6, ubiquitination assays, phosphorylation assays, lysosomal trafficking assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal approaches (pharmacological PKC activation, heterologous receptor co-stimulation, siRNA knockdown, ubiquitination, phosphorylation assays) in a single study; single lab","pmids":["30936203"],"is_preprint":false},{"year":2015,"finding":"EPI-X4, a 16-amino-acid fragment of serum albumin generated by pH-regulated proteases, is an endogenous CXCR4 antagonist; it adopts a lasso-like structure, antagonizes CXCL12-induced tumor cell migration, mobilizes stem cells in mice, and suppresses inflammatory responses.","method":"Blood-derived peptide library screen against CXCR4-tropic HIV-1, structural characterization, CXCL12-induced migration assays, in vivo stem cell mobilization assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — library screen followed by structural characterization and multiple functional assays in vitro and in vivo; single lab but multiple orthogonal methods","pmids":["25921529"],"is_preprint":false},{"year":2018,"finding":"Biased antagonism of CXCR4 by peptide X4-2-6 forms a ternary complex with the receptor and CXCL12, blocking G protein-mediated signaling and chemotaxis while permitting β-arrestin recruitment and receptor endocytosis; this avoids CXCR4 surface accumulation and antagonist tolerance, in contrast to AMD3100 which displaces all CXCL12 components.","method":"Ternary complex assays, G protein signaling assays, β-arrestin recruitment assays, receptor internalization/surface expression assays, chemotaxis assays, small-molecule biased antagonist identification","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — mechanistic dissection of biased signaling with structural complex characterization and multiple functional assays; single lab, multiple orthogonal methods","pmids":["30327409"],"is_preprint":false},{"year":2024,"finding":"Cryo-EM structures of human CXCR4 reveal that CXCL12 activates CXCR4 by inserting its N-terminus deep into the orthosteric pocket; AMD3100 binding is stabilized by electrostatic interactions with acidic residues in the seven-transmembrane-helix bundle; antibody REGN7663 inserts its CDR H3 loop into the orthosteric pocket; CXCR4 forms trimeric and tetrameric assemblies with distinct subunit conformations, suggesting that oligomerization can allosterically regulate receptor function.","method":"Cryo-electron microscopy of CXCR4 in complex with CXCL12, AMD3100, and REGN7663 antibody; structural analysis of oligomeric assemblies","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — cryo-EM structural determination with multiple ligand complexes and oligomeric states; single lab but highest-tier method","pmids":["39313635"],"is_preprint":false},{"year":2014,"finding":"CXCR4 inhibition in colon cancer cells reduces CXCL12-induced Akt phosphorylation but not ERK activation, while CXCR7 knockdown does not affect Akt or ERK; hypoxia upregulates CXCR4 (but not CXCR7) at the transcript and membrane protein level via HIF-1α, and CXCR4 expression remains stable at the membrane for up to 48 hours after return to normoxia.","method":"siRNA knockdown of CXCR4 and CXCR7, Western blotting for Akt and ERK phosphorylation, flow cytometry for membrane CXCR4, HIF-1α inhibition, hypoxia/normoxia conditions","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with multiple signaling readouts and HIF-1α dependency established; single lab","pmids":["24629239"],"is_preprint":false},{"year":2014,"finding":"CXCR4 mutations in Waldenström macroglobulinemia are heterozygous, somatic, located exclusively in the C-terminal domain, and produce a truncated receptor with higher cell-surface CXCR4 expression; these mutations are activating (gain-of-function) and occur in the same clone as MYD88 L265P mutations.","method":"Deep next-generation sequencing and Sanger sequencing of CXCR4 in patient samples; protein expression analysis; clone analysis","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct sequencing plus protein expression data from patient cohort; gain-of-function inference from C-tail truncation consistent with WHIM syndrome mechanism; single study","pmids":["26490317"],"is_preprint":false},{"year":2010,"finding":"Chronic morphine treatment upregulates CXCL12/SDF-1 in dorsal root ganglion sensory neurons and increases functional CXCR4 expression in those neurons; intraperitoneal administration of the CXCR4 antagonist AMD3100 completely reverses opioid-induced hyperalgesia in rats.","method":"RT-PCR, immunohistochemistry, functional assays in F11 neuroblastoma-sensory hybrid cells, in vivo pharmacological rescue with AMD3100","journal":"Brain, behavior, and immunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo pharmacological rescue plus cellular expression and functional assays; single lab","pmids":["21193025"],"is_preprint":false},{"year":1998,"finding":"The human CXCR4 gene has a two-exon structure; a 2.6 kb 5'-flanking region contains a TATA box, transcription start site, and consensus binding sequences for transcription factors associated with hematopoiesis and lymphocyte development.","method":"Genomic cloning, promoter characterization, identification of transcription start site and transcription factor binding sites","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct genomic characterization with promoter mapping; single lab but standard molecular biology approach","pmids":["9599023"],"is_preprint":false}],"current_model":"CXCR4 is a Gαi-coupled seven-transmembrane chemokine receptor whose sole endogenous chemokine ligand is CXCL12 (SDF-1), which binds via the receptor N-terminus and second extracellular loop to activate pertussis toxin-sensitive Gαi signaling (calcium mobilization, ERK, Akt, ZAP-70/TCR co-signaling), drive chemotaxis, and trigger C-tail serine phosphorylation-dependent β-arrestin/AIP4-mediated ubiquitination and lysosomal degradation; CXCR4 homodimerizes and also forms heterodimers with CXCR7 that dampen Gαi signaling, physically associates with the TCR to relay SDF-1 signals via ZAP-70/ITAM, and forms functional complexes with CD74 to transduce MIF signals; gain-of-function C-tail truncation mutations (WHIM syndrome, Waldenström macroglobulinemia) impair desensitization causing prolonged signaling; cryo-EM structures reveal CXCL12 N-terminus insertion into the orthosteric pocket and AMD3100 stabilization by acidic transmembrane residues, with higher-order oligomers (trimers/tetramers) adopting distinct conformations that may allosterically modulate activity; in vivo, CXCR4 is essential for haematopoietic progenitor retention in bone marrow, cardiac septation, cerebellar granule cell migration, cortical interneuron lamination (via Gαi/o), and plasma cell trafficking to bone marrow survival niches."},"narrative":{"mechanistic_narrative":"CXCR4 is a leukocyte-expressed, Gαi-coupled seven-transmembrane chemokine receptor that converts the chemokine CXCL12/SDF-1 into chemotaxis, calcium mobilization, and pro-survival kinase signaling, and that doubles as an HIV-1 entry coreceptor [PMID:8752280, PMID:8752281, PMID:8276799, PMID:8970955]. CXCL12 engages the receptor N-terminus for binding and the second extracellular loop for activation, with signaling requiring the DRY motif of the second intracellular loop and being pertussis-toxin-sensitive, whereas coreceptor function for HIV-1 is genetically separable from chemokine signaling [PMID:10074122]. Downstream, CXCR4 drives ERK and Akt phosphorylation to promote chemotaxis and protect cells from apoptosis [PMID:12388552, PMID:24629239], and in T cells it physically associates with the TCR to recruit ZAP-70 through ITAM domains, prolonging ERK activation and licensing AP-1-dependent cytokine responses [PMID:16919488]. Receptor output is shaped by partner receptors and ligand identity: CXCR7 constitutively heterodimerizes with CXCR4 and dampens Gαi activation and calcium responses [PMID:19380869], while CD74/CXCR4 complexes transduce the non-cognate ligand MIF to activate Akt [PMID:19665027, PMID:19066630]. Signal termination depends on C-terminal serine phosphorylation by GRK6 and PKC, which directs AIP4-mediated ubiquitination and lysosomal degradation; C-tail truncating gain-of-function mutations impair this desensitization and cause prolonged signaling in WHIM syndrome and Waldenström macroglobulinemia [PMID:9718374, PMID:15661033, PMID:30936203, PMID:26490317]. Genetically, CXCR4 is essential in vivo for hematopoietic and cardiac development, cerebellar granule cell migration, cortical interneuron motility and lamination via Gαi/o, and plasma cell homing to bone marrow niches [PMID:9634238, PMID:21220099, PMID:27681431]. Cryo-EM structures show CXCL12 inserting its N-terminus into the orthosteric pocket and CXCR4 assembling into trimers and tetramers whose distinct conformations can allosterically tune activity [PMID:39313635], a pocket also exploited by the endogenous albumin-derived antagonist EPI-X4 and by biased antagonists that block G-protein signaling while permitting β-arrestin recruitment [PMID:25921529, PMID:30327409].","teleology":[{"year":1994,"claim":"Establishing CXCR4 as a leukocyte seven-transmembrane GPCR defined the receptor scaffold before its ligand was known, framing the search for its activating signal.","evidence":"cDNA cloning from a monocyte library with radiolabeled ligand binding and RT-PCR expression profiling","pmids":["8276799"],"confidence":"Medium","gaps":["Natural ligand unidentified at the time","No signaling pathway assigned"]},{"year":1996,"claim":"Identifying CXCL12/SDF-1 as the natural ligand connected the orphan receptor to calcium mobilization and chemotaxis, and showed it gates HIV-1 entry.","evidence":"Receptor transfection with calcium and chemotaxis assays plus HIV-1 infection inhibition; dual-tropic coreceptor assays in CD4 cells","pmids":["8752280","8752281","8970955"],"confidence":"High","gaps":["Receptor domains required for binding versus signaling not yet mapped","G-protein coupling not directly demonstrated here"]},{"year":1998,"claim":"Knockout mice established CXCR4 as the sole in vivo SDF-1 receptor and revealed essential developmental roles, moving the receptor from a chemotaxis effector to a master patterning gene.","evidence":"Genetic knockout mouse with phenotypic analysis of hematopoiesis, cardiac, and cerebellar development; parallel endocytic and promoter mapping studies","pmids":["9634238","9718374","9599023"],"confidence":"High","gaps":["Cell-autonomous versus niche contributions not resolved","Molecular basis of distinct endocytic signals not yet linked to ubiquitination machinery"]},{"year":1999,"claim":"Domain mutagenesis separated ligand binding (N-terminus), activation (ECL2, DRY motif, Gi-coupling) and HIV coreceptor function, defining the structural logic of the receptor.","evidence":"CXCR4 chimeras and point mutants assayed for SDF-1 binding, calcium signaling, HIV infection, and pertussis toxin sensitivity","pmids":["10074122"],"confidence":"High","gaps":["Atomic-resolution ligand engagement not visualized","C-tail role in trafficking not addressed here"]},{"year":2002,"claim":"Linking CXCR4 to ERK and Akt activation and apoptosis protection established it as a pro-survival and invasion signal in cancer cells.","evidence":"Western blotting for ERK/Akt phosphorylation, serum-withdrawal apoptosis assay, and chemotaxis across glioma lines","pmids":["12388552"],"confidence":"Medium","gaps":["Branch-specific contributions of ERK versus Akt not dissected","Single cancer context"]},{"year":2006,"claim":"Discovery of physical TCR association and ZAP-70/ITAM usage showed CXCR4 can route chemokine input into antigen-receptor signaling, explaining costimulation of T cells.","evidence":"Reciprocal co-IP of CXCR4 and TCR with ZAP-70 kinase, calcium, AP-1 reporter, and cytokine secretion assays; promoter-driven transcriptional upregulation studies","pmids":["16919488","16840440"],"confidence":"High","gaps":["Stoichiometry of the CXCR4–TCR complex unknown","Generality beyond T cells not established"]},{"year":2009,"claim":"Defining CXCR7 and CD74 as heteromeric partners showed receptor output is set by partner identity, with CXCR7 dampening Gαi and CD74 enabling MIF-driven Akt signaling.","evidence":"BRET dimerization with Gi activation and calcium assays (CXCR7); reciprocal co-IP and Akt phosphorylation with antibody/inhibitor blocking (CD74)","pmids":["19380869","19665027"],"confidence":"High","gaps":["Structural basis of heterodimer-induced conformational change not resolved","Relative abundance of heteromers in vivo unclear"]},{"year":2011,"claim":"Genetic and pharmacological dissection in brain established that CXCR4 controls interneuron migration through Gαi/o, distinct from CXCR7-mediated MAPK signaling.","evidence":"Cxcr4-/- and Cxcr7-/- mice with live imaging, in vivo pertussis toxin Gαi/o inhibition, and MAPK assays; in vivo MIF co-IP from tissue","pmids":["21220099","19066630"],"confidence":"High","gaps":["Downstream cytoskeletal effectors of leading-process morphology not identified","Physiological MIF/CXCR4 role versus SDF-1 not quantified"]},{"year":2016,"claim":"WHIM-mimicking knockin and patient sequencing established that C-tail truncation is a gain-of-function lesion impairing desensitization, with disease-relevant consequences for plasma cell homing and B-cell malignancy.","evidence":"WHIM knockin mouse immunization and bone marrow analysis; deep sequencing of Waldenström macroglobulinemia patient samples; reviewed chemotaxis assays of truncation mutants","pmids":["27681431","15661033","26490317"],"confidence":"High","gaps":["Quantitative link between residual desensitization and clonal expansion not defined","Interaction with MYD88 L265P not mechanistically resolved"]},{"year":2019,"claim":"Mapping GRK6- and PKC-driven C-tail phosphorylation to AIP4-mediated ubiquitination clarified the molecular machinery that terminates CXCR4 signaling and degrades it in lysosomes.","evidence":"Phorbol ester and heterologous CXCR5 activation of PKC, GRK6 siRNA, and ubiquitination/phosphorylation/lysosomal trafficking assays","pmids":["30936203"],"confidence":"High","gaps":["Specific GRK6 phosphosites not all mapped","How truncation mutants escape this machinery not directly tested here"]},{"year":2024,"claim":"Cryo-EM structures resolved how CXCL12, AMD3100, and antibodies engage the orthosteric pocket and revealed higher-order oligomers, providing a structural framework for biased and endogenous antagonism.","evidence":"Cryo-EM of CXCR4 with CXCL12, AMD3100, and REGN7663, plus oligomer analysis; endogenous EPI-X4 antagonist characterization and biased X4-2-6 ternary-complex studies","pmids":["39313635","25921529","30327409"],"confidence":"High","gaps":["Functional consequence of trimer/tetramer states in vivo not established","Dynamics of conformational transitions during activation not captured"]},{"year":null,"claim":"How distinct CXCR4 conformational states, oligomer stoichiometries, and partner-receptor heteromers are coordinated to produce context-specific signaling outputs in vivo remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No in vivo readout linking oligomeric state to physiology","Quantitative interplay between CXCR7/CD74/TCR heteromers in native cells unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,4,9]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[0,3,4]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[10,15]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[6,9,10,21]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[17]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,4,7,8]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[8,13]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,11]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[12,22]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[5,17]}],"complexes":["CXCR4/CXCR7 heterodimer","CD74/CXCR4 complex","CXCR4/TCR complex"],"partners":["CXCL12","CXCR7","CD74","MIF","ZAP-70","AIP4","GRK6"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P61073","full_name":"C-X-C chemokine receptor type 4","aliases":["FB22","Fusin","HM89","LCR1","Leukocyte-derived seven transmembrane domain receptor","LESTR","Lipopolysaccharide-associated protein 3","LAP-3","LPS-associated protein 3","NPYRL","Stromal cell-derived factor 1 receptor","SDF-1 receptor"],"length_aa":352,"mass_kda":39.7,"function":"Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation (PubMed:10074102, PubMed:10452968, PubMed:10644702, PubMed:10825158, PubMed:18799424, PubMed:20048153, PubMed:20505072, PubMed:24912431, PubMed:28978524, PubMed:8752280, PubMed:8752281). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (PubMed:16725153, PubMed:17197449, PubMed:18799424, PubMed:39093700). CXCR4 is coupled to G(i) G alpha proteins and mediates inhibition of adenylate cyclase (PubMed:17197449, PubMed:39093700). Involved in the AKT signaling cascade (PubMed:24912431). Plays a role in regulation of cell migration, e.g. during wound healing (PubMed:28978524). Also acts as a receptor for extracellular ubiquitin; leading to enhanced intracellular calcium ions and reduced cellular cAMP levels (PubMed:20228059). Binds bacterial lipopolysaccharide (LPS) et mediates LPS-induced inflammatory response, including TNF secretion by monocytes (PubMed:11276205). Involved in hematopoiesis and in cardiac ventricular septum formation (By similarity). Also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells (By similarity). Involved in cerebellar development; in the CNS, could mediate hippocampal-neuron surviva (By similarity) (Microbial infection) Acts as a coreceptor (CD4 being the primary receptor) for human immunodeficiency virus-1/HIV-1 X4 isolates and as a primary receptor for some HIV-2 isolates. Promotes Env-mediated fusion of the virus (PubMed:10074122, PubMed:10756055, PubMed:8849450, PubMed:8929542, PubMed:9427609)","subcellular_location":"Cell membrane; Cell junction; Early endosome; Late endosome; Lysosome","url":"https://www.uniprot.org/uniprotkb/P61073/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CXCR4","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CXCR4","total_profiled":1310},"omim":[{"mim_id":"621215","title":"NANOG HOMEOBOX RETROGENE P8; NANOGP8","url":"https://www.omim.org/entry/621215"},{"mim_id":"619215","title":"OCULOMOTOR-ABDUCENS SYNKINESIS; OCABSN","url":"https://www.omim.org/entry/619215"},{"mim_id":"617486","title":"G-PATCH DOMAIN-CONTAINING PROTEIN 3; GPATCH3","url":"https://www.omim.org/entry/617486"},{"mim_id":"614596","title":"MICRO RNA 302A; MIR302A","url":"https://www.omim.org/entry/614596"},{"mim_id":"614372","title":"MANNOSE-BINDING LECTIN DEFICIENCY; MBLD","url":"https://www.omim.org/entry/614372"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":1175.0},{"tissue":"lymphoid tissue","ntpm":523.2}],"url":"https://www.proteinatlas.org/search/CXCR4"},"hgnc":{"alias_symbol":["LESTR","NPY3R","HM89","NPYY3R","D2S201E","fusin","HSY3RR","NPYR","CD184"],"prev_symbol":[]},"alphafold":{"accession":"P61073","domains":[{"cath_id":"1.20.1070.10","chopping":"33-310","consensus_level":"high","plddt":90.8728,"start":33,"end":310}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P61073","model_url":"https://alphafold.ebi.ac.uk/files/AF-P61073-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P61073-F1-predicted_aligned_error_v6.png","plddt_mean":82.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CXCR4","jax_strain_url":"https://www.jax.org/strain/search?query=CXCR4"},"sequence":{"accession":"P61073","fasta_url":"https://rest.uniprot.org/uniprotkb/P61073.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P61073/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P61073"}},"corpus_meta":[{"pmid":"9634238","id":"PMC_9634238","title":"Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development.","date":"1998","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9634238","citation_count":1994,"is_preprint":false},{"pmid":"8752280","id":"PMC_8752280","title":"The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.","date":"1996","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8752280","citation_count":1664,"is_preprint":false},{"pmid":"8752281","id":"PMC_8752281","title":"The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.","date":"1996","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8752281","citation_count":1431,"is_preprint":false},{"pmid":"20484021","id":"PMC_20484021","title":"CXCL12 (SDF-1)/CXCR4 pathway in cancer.","date":"2010","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/20484021","citation_count":1211,"is_preprint":false},{"pmid":"25287686","id":"PMC_25287686","title":"The intricate role of CXCR4 in cancer.","date":"2014","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25287686","citation_count":538,"is_preprint":false},{"pmid":"22683307","id":"PMC_22683307","title":"A review on CXCR4/CXCL12 axis in oncology: no place to hide.","date":"2012","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/22683307","citation_count":532,"is_preprint":false},{"pmid":"17169327","id":"PMC_17169327","title":"Regulation of CXCR4 signaling.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17169327","citation_count":519,"is_preprint":false},{"pmid":"19380869","id":"PMC_19380869","title":"CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19380869","citation_count":507,"is_preprint":false},{"pmid":"18987663","id":"PMC_18987663","title":"CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers.","date":"2008","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/18987663","citation_count":391,"is_preprint":false},{"pmid":"8276799","id":"PMC_8276799","title":"Cloning of a human seven-transmembrane domain receptor, LESTR, that is highly expressed in leukocytes.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8276799","citation_count":359,"is_preprint":false},{"pmid":"8970955","id":"PMC_8970955","title":"Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry.","date":"1996","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/8970955","citation_count":347,"is_preprint":false},{"pmid":"12388552","id":"PMC_12388552","title":"CXCR4 is a major chemokine receptor on glioma cells and mediates their survival.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12388552","citation_count":317,"is_preprint":false},{"pmid":"20594270","id":"PMC_20594270","title":"CXCR4 and cancer.","date":"2010","source":"Pathology international","url":"https://pubmed.ncbi.nlm.nih.gov/20594270","citation_count":239,"is_preprint":false},{"pmid":"16046252","id":"PMC_16046252","title":"Functions of CXCL12 and CXCR4 in breast cancer.","date":"2005","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/16046252","citation_count":235,"is_preprint":false},{"pmid":"21220099","id":"PMC_21220099","title":"CXCR4 and CXCR7 have distinct functions in regulating interneuron migration.","date":"2011","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/21220099","citation_count":232,"is_preprint":false},{"pmid":"11138774","id":"PMC_11138774","title":"CXCR4: chemokine receptor extraordinaire.","date":"2000","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/11138774","citation_count":218,"is_preprint":false},{"pmid":"23382786","id":"PMC_23382786","title":"Small molecule inhibitors of CXCR4.","date":"2013","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/23382786","citation_count":217,"is_preprint":false},{"pmid":"11953881","id":"PMC_11953881","title":"CXCR4/CXCL12 expression and signalling in kidney cancer.","date":"2002","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11953881","citation_count":214,"is_preprint":false},{"pmid":"27363619","id":"PMC_27363619","title":"CXCR4 signaling in health and disease.","date":"2016","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/27363619","citation_count":206,"is_preprint":false},{"pmid":"16919488","id":"PMC_16919488","title":"CXCR4 physically associates with the T cell receptor to signal in T cells.","date":"2006","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/16919488","citation_count":202,"is_preprint":false},{"pmid":"19665027","id":"PMC_19665027","title":"A functional heteromeric MIF receptor formed by CD74 and CXCR4.","date":"2009","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/19665027","citation_count":202,"is_preprint":false},{"pmid":"18533280","id":"PMC_18533280","title":"CXCR7, CXCR4 and CXCL12: an eccentric trio?","date":"2008","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/18533280","citation_count":199,"is_preprint":false},{"pmid":"10074122","id":"PMC_10074122","title":"Identification of CXCR4 domains that support coreceptor and chemokine receptor functions.","date":"1999","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/10074122","citation_count":192,"is_preprint":false},{"pmid":"26356032","id":"PMC_26356032","title":"CXCR4 in breast cancer: oncogenic role and therapeutic targeting.","date":"2015","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26356032","citation_count":183,"is_preprint":false},{"pmid":"25825601","id":"PMC_25825601","title":"Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.","date":"2015","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/25825601","citation_count":167,"is_preprint":false},{"pmid":"22989616","id":"PMC_22989616","title":"Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.","date":"2012","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22989616","citation_count":165,"is_preprint":false},{"pmid":"19339947","id":"PMC_19339947","title":"The biology of CCR5 and CXCR4.","date":"2009","source":"Current opinion in HIV and AIDS","url":"https://pubmed.ncbi.nlm.nih.gov/19339947","citation_count":163,"is_preprint":false},{"pmid":"16407848","id":"PMC_16407848","title":"CXCR4 expression mediates glioma cell invasiveness.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16407848","citation_count":157,"is_preprint":false},{"pmid":"11533159","id":"PMC_11533159","title":"Antigenically distinct conformations of CXCR4.","date":"2001","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/11533159","citation_count":137,"is_preprint":false},{"pmid":"28864616","id":"PMC_28864616","title":"CXCR4 Ligands: The Next Big Hit?","date":"2017","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28864616","citation_count":125,"is_preprint":false},{"pmid":"30791675","id":"PMC_30791675","title":"Involvement of CXCR4 in Normal and Abnormal Development.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/30791675","citation_count":122,"is_preprint":false},{"pmid":"9718374","id":"PMC_9718374","title":"Differential regulation of CXCR4 and CCR5 endocytosis.","date":"1998","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/9718374","citation_count":117,"is_preprint":false},{"pmid":"16638848","id":"PMC_16638848","title":"Human melanoma metastases express functional CXCR4.","date":"2006","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/16638848","citation_count":114,"is_preprint":false},{"pmid":"30105558","id":"PMC_30105558","title":"CXCR4-directed theranostics in oncology and inflammation.","date":"2018","source":"Annals of nuclear medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30105558","citation_count":111,"is_preprint":false},{"pmid":"9439607","id":"PMC_9439607","title":"Chemokine receptor CXCR4 expression in endothelium.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9439607","citation_count":111,"is_preprint":false},{"pmid":"9160656","id":"PMC_9160656","title":"Expression of the human immunodeficiency virus type-1 coreceptors CXCR-4 (fusin, LESTR) and CKR-5 in CD34+ hematopoietic progenitor cells.","date":"1997","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9160656","citation_count":107,"is_preprint":false},{"pmid":"26490317","id":"PMC_26490317","title":"Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia.","date":"2015","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/26490317","citation_count":105,"is_preprint":false},{"pmid":"9599023","id":"PMC_9599023","title":"Genomic organization and promoter characterization of human CXCR4 gene.","date":"1998","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9599023","citation_count":100,"is_preprint":false},{"pmid":"35674738","id":"PMC_35674738","title":"CXCR4-targeted theranostics in oncology.","date":"2022","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/35674738","citation_count":99,"is_preprint":false},{"pmid":"18644448","id":"PMC_18644448","title":"CXCL12/CXCR4 signalling in neuronal cell migration.","date":"2008","source":"Current opinion in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/18644448","citation_count":93,"is_preprint":false},{"pmid":"21082982","id":"PMC_21082982","title":"CXCL12 and CXCR4 in bone marrow physiology.","date":"2010","source":"Expert review of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/21082982","citation_count":93,"is_preprint":false},{"pmid":"19216844","id":"PMC_19216844","title":"The chemokine receptors CXCR4 and CXCR3 in cancer.","date":"2009","source":"Current oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/19216844","citation_count":93,"is_preprint":false},{"pmid":"23279723","id":"PMC_23279723","title":"An infernal trio: the chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology.","date":"2012","source":"Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft","url":"https://pubmed.ncbi.nlm.nih.gov/23279723","citation_count":87,"is_preprint":false},{"pmid":"33014834","id":"PMC_33014834","title":"Targeting CXCR4 in AML and ALL.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33014834","citation_count":85,"is_preprint":false},{"pmid":"16840440","id":"PMC_16840440","title":"HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-kappaB.","date":"2006","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/16840440","citation_count":85,"is_preprint":false},{"pmid":"29903571","id":"PMC_29903571","title":"Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.","date":"2018","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/29903571","citation_count":81,"is_preprint":false},{"pmid":"21193025","id":"PMC_21193025","title":"CXCR4 signaling mediates morphine-induced tactile hyperalgesia.","date":"2010","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/21193025","citation_count":79,"is_preprint":false},{"pmid":"25921529","id":"PMC_25921529","title":"Discovery and characterization of an endogenous CXCR4 antagonist.","date":"2015","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/25921529","citation_count":77,"is_preprint":false},{"pmid":"29636460","id":"PMC_29636460","title":"CXCR4 involvement in neurodegenerative diseases.","date":"2018","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/29636460","citation_count":75,"is_preprint":false},{"pmid":"22283809","id":"PMC_22283809","title":"Development of novel CXCR4-based therapeutics.","date":"2012","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/22283809","citation_count":75,"is_preprint":false},{"pmid":"23382787","id":"PMC_23382787","title":"Molecular imaging of chemokine receptor CXCR4.","date":"2013","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/23382787","citation_count":73,"is_preprint":false},{"pmid":"33273682","id":"PMC_33273682","title":"CXCR4 in Waldenström's Macroglobulinema: chances and challenges.","date":"2020","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/33273682","citation_count":72,"is_preprint":false},{"pmid":"14702198","id":"PMC_14702198","title":"SDF-1 and CXCR4 in normal and malignant hematopoiesis.","date":"2004","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/14702198","citation_count":72,"is_preprint":false},{"pmid":"19625779","id":"PMC_19625779","title":"CXCL12, CXCR4 and CXCR7 expression in brain metastases.","date":"2009","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19625779","citation_count":72,"is_preprint":false},{"pmid":"29288743","id":"PMC_29288743","title":"The good and bad faces of the CXCR4 chemokine receptor.","date":"2017","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29288743","citation_count":70,"is_preprint":false},{"pmid":"22743644","id":"PMC_22743644","title":"Imaging agents for the chemokine receptor 4 (CXCR4).","date":"2012","source":"Chemical Society reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22743644","citation_count":70,"is_preprint":false},{"pmid":"24629239","id":"PMC_24629239","title":"Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer.","date":"2014","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24629239","citation_count":68,"is_preprint":false},{"pmid":"17325742","id":"PMC_17325742","title":"Tissue microenvironment modulates CXCR4 expression and tumor metastasis in neuroblastoma.","date":"2007","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/17325742","citation_count":65,"is_preprint":false},{"pmid":"26353174","id":"PMC_26353174","title":"CXCL12/CXCR4 axis: an emerging neuromodulator in pathological pain.","date":"2016","source":"Reviews in the neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/26353174","citation_count":59,"is_preprint":false},{"pmid":"29398278","id":"PMC_29398278","title":"Multisystem multitasking by CXCL12 and its receptors CXCR4 and ACKR3.","date":"2018","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/29398278","citation_count":58,"is_preprint":false},{"pmid":"19335276","id":"PMC_19335276","title":"CXCR4 chemokine receptor antagonists: perspectives in SCLC.","date":"2009","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/19335276","citation_count":58,"is_preprint":false},{"pmid":"20147779","id":"PMC_20147779","title":"The role of chemokine receptor CXCR4 in lung cancer.","date":"2010","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/20147779","citation_count":58,"is_preprint":false},{"pmid":"15661033","id":"PMC_15661033","title":"CXCR4 mutations in WHIM syndrome: a misguided immune system?","date":"2005","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/15661033","citation_count":58,"is_preprint":false},{"pmid":"31475113","id":"PMC_31475113","title":"CXCR4-Directed Imaging in Solid Tumors.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31475113","citation_count":57,"is_preprint":false},{"pmid":"39236316","id":"PMC_39236316","title":"SPP1+ TAM Regulates the Metastatic Colonization of CXCR4+ Metastasis-Associated Tumor Cells by Remodeling the Lymph Node Microenvironment.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39236316","citation_count":53,"is_preprint":false},{"pmid":"22186993","id":"PMC_22186993","title":"Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22186993","citation_count":52,"is_preprint":false},{"pmid":"25537742","id":"PMC_25537742","title":"Chemokine receptor Cxcr4 contributes to kidney fibrosis via multiple effectors.","date":"2014","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25537742","citation_count":52,"is_preprint":false},{"pmid":"19594447","id":"PMC_19594447","title":"Bioluminescent CXCL12 fusion protein for cellular studies of CXCR4 and CXCR7.","date":"2009","source":"BioTechniques","url":"https://pubmed.ncbi.nlm.nih.gov/19594447","citation_count":52,"is_preprint":false},{"pmid":"30342024","id":"PMC_30342024","title":"CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry.","date":"2018","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30342024","citation_count":51,"is_preprint":false},{"pmid":"22376154","id":"PMC_22376154","title":"CXCR4 inhibitors: tumor vasculature and therapeutic challenges.","date":"2012","source":"Recent patents on anti-cancer drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/22376154","citation_count":51,"is_preprint":false},{"pmid":"28526063","id":"PMC_28526063","title":"Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.","date":"2017","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28526063","citation_count":51,"is_preprint":false},{"pmid":"31548340","id":"PMC_31548340","title":"Modulators of CXCR4 and CXCR7/ACKR3 Function.","date":"2019","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31548340","citation_count":50,"is_preprint":false},{"pmid":"17176471","id":"PMC_17176471","title":"Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma.","date":"2006","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17176471","citation_count":49,"is_preprint":false},{"pmid":"24816217","id":"PMC_24816217","title":"CXCR4 blockade induces atherosclerosis by affecting neutrophil function.","date":"2014","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/24816217","citation_count":49,"is_preprint":false},{"pmid":"26299663","id":"PMC_26299663","title":"CXCR4 and Glioblastoma.","date":"2016","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26299663","citation_count":48,"is_preprint":false},{"pmid":"22045705","id":"PMC_22045705","title":"CXCR4-based imaging agents.","date":"2011","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22045705","citation_count":46,"is_preprint":false},{"pmid":"24120239","id":"PMC_24120239","title":"Chemokine receptor CXCR4: role in gastrointestinal cancer.","date":"2013","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/24120239","citation_count":45,"is_preprint":false},{"pmid":"27681431","id":"PMC_27681431","title":"Efficient Plasma Cell Differentiation and Trafficking Require Cxcr4 Desensitization.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27681431","citation_count":45,"is_preprint":false},{"pmid":"16091205","id":"PMC_16091205","title":"WHIM syndrome: a defect in CXCR4 signaling.","date":"2005","source":"Current allergy and asthma reports","url":"https://pubmed.ncbi.nlm.nih.gov/16091205","citation_count":42,"is_preprint":false},{"pmid":"31481460","id":"PMC_31481460","title":"Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3.","date":"2019","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31481460","citation_count":40,"is_preprint":false},{"pmid":"20580441","id":"PMC_20580441","title":"CXCR4-mediated glutamate exocytosis from astrocytes.","date":"2010","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/20580441","citation_count":40,"is_preprint":false},{"pmid":"19066630","id":"PMC_19066630","title":"Cyclophosphamide-induced cystitis increases bladder CXCR4 expression and CXCR4-macrophage migration inhibitory factor association.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19066630","citation_count":40,"is_preprint":false},{"pmid":"33123122","id":"PMC_33123122","title":"CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33123122","citation_count":40,"is_preprint":false},{"pmid":"26369824","id":"PMC_26369824","title":"Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway.","date":"2016","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26369824","citation_count":39,"is_preprint":false},{"pmid":"25372750","id":"PMC_25372750","title":"CXCL14 antagonizes the CXCL12-CXCR4 signaling axis.","date":"2014","source":"Biomolecular concepts","url":"https://pubmed.ncbi.nlm.nih.gov/25372750","citation_count":39,"is_preprint":false},{"pmid":"35406582","id":"PMC_35406582","title":"Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35406582","citation_count":38,"is_preprint":false},{"pmid":"26551719","id":"PMC_26551719","title":"Role of chemokine receptors CXCR4 and CXCR7 for platelet function.","date":"2015","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/26551719","citation_count":38,"is_preprint":false},{"pmid":"34885030","id":"PMC_34885030","title":"In Vivo Targeting of CXCR4-New Horizons.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34885030","citation_count":37,"is_preprint":false},{"pmid":"36905421","id":"PMC_36905421","title":"CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment.","date":"2023","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36905421","citation_count":36,"is_preprint":false},{"pmid":"36058380","id":"PMC_36058380","title":"Demystifying the CXCR4 conundrum in cancer biology: Beyond the surface signaling paradigm.","date":"2022","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36058380","citation_count":36,"is_preprint":false},{"pmid":"21294125","id":"PMC_21294125","title":"The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.","date":"2011","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21294125","citation_count":36,"is_preprint":false},{"pmid":"30327409","id":"PMC_30327409","title":"Biased antagonism of CXCR4 avoids antagonist tolerance.","date":"2018","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/30327409","citation_count":35,"is_preprint":false},{"pmid":"39313635","id":"PMC_39313635","title":"Structural insights into CXCR4 modulation and oligomerization.","date":"2024","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/39313635","citation_count":34,"is_preprint":false},{"pmid":"29146630","id":"PMC_29146630","title":"A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination.","date":"2017","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/29146630","citation_count":34,"is_preprint":false},{"pmid":"25451233","id":"PMC_25451233","title":"CXCL14 is no direct modulator of CXCR4.","date":"2014","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/25451233","citation_count":32,"is_preprint":false},{"pmid":"35772647","id":"PMC_35772647","title":"Zedoarondiol inhibits atherosclerosis by regulating monocyte migration and adhesion via CXCL12/CXCR4 pathway.","date":"2022","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/35772647","citation_count":30,"is_preprint":false},{"pmid":"18624812","id":"PMC_18624812","title":"CXCR4, inhibitors and mechanisms of action.","date":"2008","source":"Chemical biology & drug design","url":"https://pubmed.ncbi.nlm.nih.gov/18624812","citation_count":29,"is_preprint":false},{"pmid":"26082201","id":"PMC_26082201","title":"Urokinase receptor and CXCR4 are regulated by common microRNAs in leukaemia cells.","date":"2015","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26082201","citation_count":28,"is_preprint":false},{"pmid":"30936203","id":"PMC_30936203","title":"Heterologous regulation of CXCR4 lysosomal trafficking.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30936203","citation_count":27,"is_preprint":false},{"pmid":"24879309","id":"PMC_24879309","title":"The CXCR4/CXCL12 axis in cutaneous malignancies with an emphasis on melanoma.","date":"2014","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/24879309","citation_count":27,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48484,"output_tokens":6777,"usd":0.123553,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15572,"output_tokens":4278,"usd":0.092405,"stage2_stop_reason":"end_turn"},"total_usd":0.215958,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"SDF-1 (CXCL12) is the natural ligand for CXCR4 (LESTR/fusin); SDF-1 signals through CXCR4 to induce intracellular Ca2+ increase and chemotaxis in CXCR4-transfected cells, and blocks T-tropic HIV-1 infection of CD4+ cells expressing CXCR4.\",\n      \"method\": \"Receptor transfection assays, Ca2+ mobilization assay, chemotaxis assay, HIV-1 infection inhibition assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — two independent papers replicated in the same issue using transfection, functional calcium assay, chemotaxis, and viral infection assays\",\n      \"pmids\": [\"8752280\", \"8752281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CXCR4 (LESTR) was cloned as a novel seven-transmembrane, GTP-binding protein-coupled receptor highly expressed in leukocytes; transfected cells expressing LESTR did not bind IL-8, NPY, or a panel of other chemotactic ligands, leaving its natural ligand unidentified at that time.\",\n      \"method\": \"cDNA cloning from monocyte library, radiolabeled ligand binding assays, RT-PCR expression profiling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — initial molecular cloning with binding assays; negative ligand identification result is mechanistically informative; single lab\",\n      \"pmids\": [\"8276799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CXCR4-knockout mice exhibit haematopoietic and cardiac defects identical to those of SDF-1-deficient mice, indicating CXCR4 is the sole receptor for SDF-1 in vivo; CXCR4 loss also causes cerebellar granule cell migration defects, establishing CXCR4 as required for neuronal cell migration and patterning.\",\n      \"method\": \"Genetic knockout mouse model, phenotypic analysis of haematopoiesis, cardiac development, and cerebellar development\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function mouse model with specific cellular phenotypes; replicated against SDF-1 KO phenotype as epistatic control\",\n      \"pmids\": [\"9634238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Primary syncytium-inducing HIV-1 strains are dual-tropic and can use either CXCR4 (LESTR/fusin) or CCR5 as co-receptors for entry into CD4+ cells.\",\n      \"method\": \"Infection assays using cat CCC/CD4 cells transiently expressing LESTR or CCR5\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct viral infection assay in receptor-transfected cells; single lab but clear functional readout\",\n      \"pmids\": [\"8970955\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"SDF-1 requires the CXCR4 N-terminus for binding and activates downstream signaling through the second extracellular loop; activation requires the Asp-Arg-Tyr motif in the second intracellular loop and is pertussis-toxin sensitive (Gi-coupled). The C-terminal tail is dispensable for signaling. Several CXCR4 mutants unable to bind SDF-1 or signal still support HIV-1 infection, indicating that coreceptor function is independent of chemokine signaling.\",\n      \"method\": \"CXCR4 chimeras and point mutants, SDF-1 binding assays, calcium signaling assays, HIV-1 infection assays, pertussis toxin treatment\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis of defined domains with multiple functional readouts (binding, signaling, viral entry) in a single systematic study\",\n      \"pmids\": [\"10074122\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CXCR4 endocytosis is mediated by two distinct signals: a C-terminal serine-rich domain is required for ligand-induced but not phorbol ester-induced internalization, while a Ser/IleLeu motif mediates phorbol ester-induced but not ligand-induced endocytosis.\",\n      \"method\": \"CXCR4 deletion/mutation constructs, internalization assays in T cells, phorbol ester and SDF-1 stimulation\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis dissecting two independent endocytic pathways with clear functional readouts; single lab, multiple orthogonal conditions\",\n      \"pmids\": [\"9718374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CXCR4 exists in antigenically distinct conformational states on primary T and B cells; conformational heterogeneity is not due to glycosylation, sulfation of the N-terminal domain, or pertussis toxin-sensitive G-protein coupling. The commonly used anti-CXCR4 antibody 12G5 recognizes only a subpopulation of CXCR4 molecules on primary cells.\",\n      \"method\": \"Monoclonal antibody panel, flow cytometry, chemotaxis assay, HIV-1 infection inhibition, pertussis toxin treatment, glycosylation and sulfation analysis\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple MAbs and orthogonal functional assays; single lab\",\n      \"pmids\": [\"11533159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CXCR4 activation by SDF-1 (CXCL12) in glioma cells induces rapid phosphorylation of MAP kinases (ERK) and Akt (PKB), and protects glioma cells from serum withdrawal-induced apoptosis; CXCR4 also mediates glioma cell chemotaxis.\",\n      \"method\": \"Western blotting for ERK and Akt phosphorylation, apoptosis assay (serum withdrawal), Boyden chamber chemotaxis assay, receptor expression profiling across 16 glioma lines\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays (survival, ERK, Akt, chemotaxis) in multiple glioma lines; single lab\",\n      \"pmids\": [\"12388552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CXCR4 physically associates with the T cell receptor (TCR) upon SDF-1α stimulation, and utilizes ITAM domains of the TCR to activate ZAP-70 tyrosine kinase, leading to prolonged ERK MAP kinase activation, increased intracellular calcium, robust AP-1 transcriptional activity, and SDF-1α costimulation of cytokine secretion in T cells.\",\n      \"method\": \"Co-immunoprecipitation of CXCR4 and TCR, ZAP-70 kinase assays, ERK phosphorylation assays, calcium flux assays, AP-1 reporter assay, cytokine secretion assay\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP plus multiple orthogonal functional readouts (kinase activity, calcium, transcription, cytokine) in a single study; single lab\",\n      \"pmids\": [\"16919488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CXCR7 constitutively heterodimerizes with CXCR4 as efficiently as homodimerization; CXCR7 expression induces conformational rearrangements within preassembled CXCR4/Gαi protein complexes and impairs CXCR4-promoted Gαi-protein activation and calcium responses to CXCL12.\",\n      \"method\": \"BRET/energy transfer dimerization assays, G protein activation assays, calcium mobilization assays, primary T cell chemotaxis with CXCR4 pharmacological blockade\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — energy transfer assays plus functional signaling readouts (Gi activation, calcium, chemotaxis) in both transfected and primary cells; single lab\",\n      \"pmids\": [\"19380869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CD74 forms functional heteromeric complexes with CXCR4 at the cell surface; these CD74/CXCR4 complexes mediate MIF-specific AKT activation that is blocked by anti-CXCR4 antibodies and AMD3100, while CXCL12-stimulated AKT activation is not reduced by anti-CD74.\",\n      \"method\": \"Co-immunoprecipitation from HEK293 cells and from primary monocytes, AKT phosphorylation assays, antibody/inhibitor blocking experiments\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP in transfected and primary cells plus functional signaling assay; single lab\",\n      \"pmids\": [\"19665027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CXCR4 and CXCR7 have distinct roles in cortical interneuron migration: CXCR4 loss leads to interneuron motility defects and altered leading process morphology, and in vivo inhibition of Gαi/o signaling phenocopies Cxcr4-knockout lamination defects, whereas CXCL12 stimulation of CXCR7 (but not CXCR4) promotes MAP kinase signaling.\",\n      \"method\": \"Cxcr4-/- and Cxcr7-/- knockout mice, live imaging of migrating interneurons, pharmacological CXCR4 blockade, in vivo pertussis toxin-mediated Gαi/o inhibition, MAPK signaling assays\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic knockouts, live imaging, pharmacological tools, and signaling assays across multiple orthogonal approaches; single lab but highly rigorous\",\n      \"pmids\": [\"21220099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"WHIM syndrome mutations in CXCR4 truncate the cytoplasmic tail, impairing receptor downregulation/desensitization and causing enhanced (gain-of-function) chemotaxis in response to CXCL12, establishing that CXCR4 C-tail truncation leads to aberrant prolonged signaling.\",\n      \"method\": \"Analysis of patient-derived CXCR4 mutations, chemotaxis assays with mutant receptor, biochemical studies of receptor desensitization\",\n      \"journal\": \"Immunological reviews\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional chemotaxis assays with mutant receptors in patient-derived and transfected cell contexts; reviewed finding corroborated by multiple studies\",\n      \"pmids\": [\"15661033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Fine-tuning of CXCR4 desensitization is required for efficient plasma cell (PC) differentiation, trafficking, and bone marrow maintenance; a gain-of-function CXCR4 knockin mutation (phenocopying WHIM syndrome) intrinsically promotes germinal center response and PC differentiation but prevents antigen-specific PCs from homing to bone marrow survival niches, correlating with early accumulation of immature plasmablasts.\",\n      \"method\": \"WHIM syndrome knockin mouse model, immunization experiments, flow cytometry, antibody titer measurement, bone marrow analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockin mouse model with specific cellular and functional phenotypes across multiple readouts; single lab\",\n      \"pmids\": [\"27681431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"HGF upregulates CXCR4 transcription in MCF-7 breast cancer cells via Ets1 (activated by MAPK1/ERK1/2) and NF-κB cooperating at the CXCR4 promoter; blocking these transcription factors with dominant negatives or inhibitors prevented CXCR4 induction and CXCL12-directed chemoinvasion. Hypoxia upregulates CXCR4 via HIF-1 and NF-κB.\",\n      \"method\": \"Dominant negative transcription factor constructs, pharmacological inhibitors, CXCR4 promoter-reporter assay, Boyden chamber chemoinvasion assay, Western blotting\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter-reporter, dominant negatives, and functional invasion assay; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"16840440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CXCR4-MIF (macrophage migration inhibitory factor) complexes occur in vivo in rat bladder urothelium and are detected by co-immunoprecipitation; cyclophosphamide-induced cystitis increases CXCR4 expression and CXCR4-MIF associations, and MIF-stimulated signaling through CXCR4 represents an alternative, non-cognate ligand pathway distinct from SDF-1/CXCR4 signaling.\",\n      \"method\": \"Co-immunoprecipitation from bladder tissue, immunohistochemistry, Western blotting, ELISA, real-time RT-PCR\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP from tissue in vivo plus multiple corroborating assays; single lab\",\n      \"pmids\": [\"19066630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In kidney fibrosis (unilateral ureteral obstruction model), CXCR4 expression is upregulated in tubular cells and correlates with increased TGF-β1, PDGF-α, and decreased BMP7; genetic ablation of CXCR4 from tubular cells or macrophages attenuates fibrosis, Smad activation, and α-smooth muscle actin levels, revealing a CXCR4–TGF-β1–BMP7 pathway cross-talk in renal fibrosis.\",\n      \"method\": \"Cell-type-specific CXCR4 genetic knockout, unilateral ureteral obstruction model, Western blotting for TGF-β1/PDGF-α/BMP7/Smad/α-SMA, histology\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific knockouts with defined molecular pathway readouts; single lab\",\n      \"pmids\": [\"25537742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PKC and GRK6 contribute to CXCR4 lysosomal trafficking and degradation via distinct mechanisms: PKC (activated heterologously by CXCR5/CXCL13 or phorbol ester) phosphorylates serine residues in the CXCR4 C-tail required for AIP4 (E3 ubiquitin ligase) binding and ubiquitination; GRK6 depletion by siRNA reduces CXCR4 degradation and ubiquitination. PKC inhibition does not alter CXCL12-mediated ubiquitination, indicating that GRK6 acts through a separate mechanism.\",\n      \"method\": \"PKC activation by phorbol ester (PMA) and heterologous CXCR5/CXCL13 stimulation, siRNA depletion of GRK6, ubiquitination assays, phosphorylation assays, lysosomal trafficking assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal approaches (pharmacological PKC activation, heterologous receptor co-stimulation, siRNA knockdown, ubiquitination, phosphorylation assays) in a single study; single lab\",\n      \"pmids\": [\"30936203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EPI-X4, a 16-amino-acid fragment of serum albumin generated by pH-regulated proteases, is an endogenous CXCR4 antagonist; it adopts a lasso-like structure, antagonizes CXCL12-induced tumor cell migration, mobilizes stem cells in mice, and suppresses inflammatory responses.\",\n      \"method\": \"Blood-derived peptide library screen against CXCR4-tropic HIV-1, structural characterization, CXCL12-induced migration assays, in vivo stem cell mobilization assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — library screen followed by structural characterization and multiple functional assays in vitro and in vivo; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"25921529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Biased antagonism of CXCR4 by peptide X4-2-6 forms a ternary complex with the receptor and CXCL12, blocking G protein-mediated signaling and chemotaxis while permitting β-arrestin recruitment and receptor endocytosis; this avoids CXCR4 surface accumulation and antagonist tolerance, in contrast to AMD3100 which displaces all CXCL12 components.\",\n      \"method\": \"Ternary complex assays, G protein signaling assays, β-arrestin recruitment assays, receptor internalization/surface expression assays, chemotaxis assays, small-molecule biased antagonist identification\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mechanistic dissection of biased signaling with structural complex characterization and multiple functional assays; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"30327409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structures of human CXCR4 reveal that CXCL12 activates CXCR4 by inserting its N-terminus deep into the orthosteric pocket; AMD3100 binding is stabilized by electrostatic interactions with acidic residues in the seven-transmembrane-helix bundle; antibody REGN7663 inserts its CDR H3 loop into the orthosteric pocket; CXCR4 forms trimeric and tetrameric assemblies with distinct subunit conformations, suggesting that oligomerization can allosterically regulate receptor function.\",\n      \"method\": \"Cryo-electron microscopy of CXCR4 in complex with CXCL12, AMD3100, and REGN7663 antibody; structural analysis of oligomeric assemblies\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — cryo-EM structural determination with multiple ligand complexes and oligomeric states; single lab but highest-tier method\",\n      \"pmids\": [\"39313635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CXCR4 inhibition in colon cancer cells reduces CXCL12-induced Akt phosphorylation but not ERK activation, while CXCR7 knockdown does not affect Akt or ERK; hypoxia upregulates CXCR4 (but not CXCR7) at the transcript and membrane protein level via HIF-1α, and CXCR4 expression remains stable at the membrane for up to 48 hours after return to normoxia.\",\n      \"method\": \"siRNA knockdown of CXCR4 and CXCR7, Western blotting for Akt and ERK phosphorylation, flow cytometry for membrane CXCR4, HIF-1α inhibition, hypoxia/normoxia conditions\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with multiple signaling readouts and HIF-1α dependency established; single lab\",\n      \"pmids\": [\"24629239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CXCR4 mutations in Waldenström macroglobulinemia are heterozygous, somatic, located exclusively in the C-terminal domain, and produce a truncated receptor with higher cell-surface CXCR4 expression; these mutations are activating (gain-of-function) and occur in the same clone as MYD88 L265P mutations.\",\n      \"method\": \"Deep next-generation sequencing and Sanger sequencing of CXCR4 in patient samples; protein expression analysis; clone analysis\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct sequencing plus protein expression data from patient cohort; gain-of-function inference from C-tail truncation consistent with WHIM syndrome mechanism; single study\",\n      \"pmids\": [\"26490317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Chronic morphine treatment upregulates CXCL12/SDF-1 in dorsal root ganglion sensory neurons and increases functional CXCR4 expression in those neurons; intraperitoneal administration of the CXCR4 antagonist AMD3100 completely reverses opioid-induced hyperalgesia in rats.\",\n      \"method\": \"RT-PCR, immunohistochemistry, functional assays in F11 neuroblastoma-sensory hybrid cells, in vivo pharmacological rescue with AMD3100\",\n      \"journal\": \"Brain, behavior, and immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo pharmacological rescue plus cellular expression and functional assays; single lab\",\n      \"pmids\": [\"21193025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The human CXCR4 gene has a two-exon structure; a 2.6 kb 5'-flanking region contains a TATA box, transcription start site, and consensus binding sequences for transcription factors associated with hematopoiesis and lymphocyte development.\",\n      \"method\": \"Genomic cloning, promoter characterization, identification of transcription start site and transcription factor binding sites\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct genomic characterization with promoter mapping; single lab but standard molecular biology approach\",\n      \"pmids\": [\"9599023\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CXCR4 is a Gαi-coupled seven-transmembrane chemokine receptor whose sole endogenous chemokine ligand is CXCL12 (SDF-1), which binds via the receptor N-terminus and second extracellular loop to activate pertussis toxin-sensitive Gαi signaling (calcium mobilization, ERK, Akt, ZAP-70/TCR co-signaling), drive chemotaxis, and trigger C-tail serine phosphorylation-dependent β-arrestin/AIP4-mediated ubiquitination and lysosomal degradation; CXCR4 homodimerizes and also forms heterodimers with CXCR7 that dampen Gαi signaling, physically associates with the TCR to relay SDF-1 signals via ZAP-70/ITAM, and forms functional complexes with CD74 to transduce MIF signals; gain-of-function C-tail truncation mutations (WHIM syndrome, Waldenström macroglobulinemia) impair desensitization causing prolonged signaling; cryo-EM structures reveal CXCL12 N-terminus insertion into the orthosteric pocket and AMD3100 stabilization by acidic transmembrane residues, with higher-order oligomers (trimers/tetramers) adopting distinct conformations that may allosterically modulate activity; in vivo, CXCR4 is essential for haematopoietic progenitor retention in bone marrow, cardiac septation, cerebellar granule cell migration, cortical interneuron lamination (via Gαi/o), and plasma cell trafficking to bone marrow survival niches.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CXCR4 is a leukocyte-expressed, Gαi-coupled seven-transmembrane chemokine receptor that converts the chemokine CXCL12/SDF-1 into chemotaxis, calcium mobilization, and pro-survival kinase signaling, and that doubles as an HIV-1 entry coreceptor [#0, #1, #3]. CXCL12 engages the receptor N-terminus for binding and the second extracellular loop for activation, with signaling requiring the DRY motif of the second intracellular loop and being pertussis-toxin-sensitive, whereas coreceptor function for HIV-1 is genetically separable from chemokine signaling [#4]. Downstream, CXCR4 drives ERK and Akt phosphorylation to promote chemotaxis and protect cells from apoptosis [#7, #21], and in T cells it physically associates with the TCR to recruit ZAP-70 through ITAM domains, prolonging ERK activation and licensing AP-1-dependent cytokine responses [#8]. Receptor output is shaped by partner receptors and ligand identity: CXCR7 constitutively heterodimerizes with CXCR4 and dampens Gαi activation and calcium responses [#9], while CD74/CXCR4 complexes transduce the non-cognate ligand MIF to activate Akt [#10, #15]. Signal termination depends on C-terminal serine phosphorylation by GRK6 and PKC, which directs AIP4-mediated ubiquitination and lysosomal degradation; C-tail truncating gain-of-function mutations impair this desensitization and cause prolonged signaling in WHIM syndrome and Waldenström macroglobulinemia [#5, #12, #17, #22]. Genetically, CXCR4 is essential in vivo for hematopoietic and cardiac development, cerebellar granule cell migration, cortical interneuron motility and lamination via Gαi/o, and plasma cell homing to bone marrow niches [#2, #11, #13]. Cryo-EM structures show CXCL12 inserting its N-terminus into the orthosteric pocket and CXCR4 assembling into trimers and tetramers whose distinct conformations can allosterically tune activity [#20], a pocket also exploited by the endogenous albumin-derived antagonist EPI-X4 and by biased antagonists that block G-protein signaling while permitting β-arrestin recruitment [#18, #19].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing CXCR4 as a leukocyte seven-transmembrane GPCR defined the receptor scaffold before its ligand was known, framing the search for its activating signal.\",\n      \"evidence\": \"cDNA cloning from a monocyte library with radiolabeled ligand binding and RT-PCR expression profiling\",\n      \"pmids\": [\"8276799\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Natural ligand unidentified at the time\", \"No signaling pathway assigned\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identifying CXCL12/SDF-1 as the natural ligand connected the orphan receptor to calcium mobilization and chemotaxis, and showed it gates HIV-1 entry.\",\n      \"evidence\": \"Receptor transfection with calcium and chemotaxis assays plus HIV-1 infection inhibition; dual-tropic coreceptor assays in CD4 cells\",\n      \"pmids\": [\"8752280\", \"8752281\", \"8970955\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor domains required for binding versus signaling not yet mapped\", \"G-protein coupling not directly demonstrated here\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Knockout mice established CXCR4 as the sole in vivo SDF-1 receptor and revealed essential developmental roles, moving the receptor from a chemotaxis effector to a master patterning gene.\",\n      \"evidence\": \"Genetic knockout mouse with phenotypic analysis of hematopoiesis, cardiac, and cerebellar development; parallel endocytic and promoter mapping studies\",\n      \"pmids\": [\"9634238\", \"9718374\", \"9599023\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-autonomous versus niche contributions not resolved\", \"Molecular basis of distinct endocytic signals not yet linked to ubiquitination machinery\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Domain mutagenesis separated ligand binding (N-terminus), activation (ECL2, DRY motif, Gi-coupling) and HIV coreceptor function, defining the structural logic of the receptor.\",\n      \"evidence\": \"CXCR4 chimeras and point mutants assayed for SDF-1 binding, calcium signaling, HIV infection, and pertussis toxin sensitivity\",\n      \"pmids\": [\"10074122\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic-resolution ligand engagement not visualized\", \"C-tail role in trafficking not addressed here\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Linking CXCR4 to ERK and Akt activation and apoptosis protection established it as a pro-survival and invasion signal in cancer cells.\",\n      \"evidence\": \"Western blotting for ERK/Akt phosphorylation, serum-withdrawal apoptosis assay, and chemotaxis across glioma lines\",\n      \"pmids\": [\"12388552\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Branch-specific contributions of ERK versus Akt not dissected\", \"Single cancer context\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Discovery of physical TCR association and ZAP-70/ITAM usage showed CXCR4 can route chemokine input into antigen-receptor signaling, explaining costimulation of T cells.\",\n      \"evidence\": \"Reciprocal co-IP of CXCR4 and TCR with ZAP-70 kinase, calcium, AP-1 reporter, and cytokine secretion assays; promoter-driven transcriptional upregulation studies\",\n      \"pmids\": [\"16919488\", \"16840440\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the CXCR4–TCR complex unknown\", \"Generality beyond T cells not established\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defining CXCR7 and CD74 as heteromeric partners showed receptor output is set by partner identity, with CXCR7 dampening Gαi and CD74 enabling MIF-driven Akt signaling.\",\n      \"evidence\": \"BRET dimerization with Gi activation and calcium assays (CXCR7); reciprocal co-IP and Akt phosphorylation with antibody/inhibitor blocking (CD74)\",\n      \"pmids\": [\"19380869\", \"19665027\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of heterodimer-induced conformational change not resolved\", \"Relative abundance of heteromers in vivo unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Genetic and pharmacological dissection in brain established that CXCR4 controls interneuron migration through Gαi/o, distinct from CXCR7-mediated MAPK signaling.\",\n      \"evidence\": \"Cxcr4-/- and Cxcr7-/- mice with live imaging, in vivo pertussis toxin Gαi/o inhibition, and MAPK assays; in vivo MIF co-IP from tissue\",\n      \"pmids\": [\"21220099\", \"19066630\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream cytoskeletal effectors of leading-process morphology not identified\", \"Physiological MIF/CXCR4 role versus SDF-1 not quantified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"WHIM-mimicking knockin and patient sequencing established that C-tail truncation is a gain-of-function lesion impairing desensitization, with disease-relevant consequences for plasma cell homing and B-cell malignancy.\",\n      \"evidence\": \"WHIM knockin mouse immunization and bone marrow analysis; deep sequencing of Waldenström macroglobulinemia patient samples; reviewed chemotaxis assays of truncation mutants\",\n      \"pmids\": [\"27681431\", \"15661033\", \"26490317\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative link between residual desensitization and clonal expansion not defined\", \"Interaction with MYD88 L265P not mechanistically resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Mapping GRK6- and PKC-driven C-tail phosphorylation to AIP4-mediated ubiquitination clarified the molecular machinery that terminates CXCR4 signaling and degrades it in lysosomes.\",\n      \"evidence\": \"Phorbol ester and heterologous CXCR5 activation of PKC, GRK6 siRNA, and ubiquitination/phosphorylation/lysosomal trafficking assays\",\n      \"pmids\": [\"30936203\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific GRK6 phosphosites not all mapped\", \"How truncation mutants escape this machinery not directly tested here\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Cryo-EM structures resolved how CXCL12, AMD3100, and antibodies engage the orthosteric pocket and revealed higher-order oligomers, providing a structural framework for biased and endogenous antagonism.\",\n      \"evidence\": \"Cryo-EM of CXCR4 with CXCL12, AMD3100, and REGN7663, plus oligomer analysis; endogenous EPI-X4 antagonist characterization and biased X4-2-6 ternary-complex studies\",\n      \"pmids\": [\"39313635\", \"25921529\", \"30327409\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of trimer/tetramer states in vivo not established\", \"Dynamics of conformational transitions during activation not captured\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How distinct CXCR4 conformational states, oligomer stoichiometries, and partner-receptor heteromers are coordinated to produce context-specific signaling outputs in vivo remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No in vivo readout linking oligomeric state to physiology\", \"Quantitative interplay between CXCR7/CD74/TCR heteromers in native cells unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 4, 9]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [0, 3, 4]},\n      {\"term_id\": \"GO:0004930\", \"supporting_discovery_ids\": [0, 1, 4]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [10, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6, 9, 10, 21]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 4, 7, 8]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8, 13]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 11]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [12, 22]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [5, 17]}\n    ],\n    \"complexes\": [\n      \"CXCR4/CXCR7 heterodimer\",\n      \"CD74/CXCR4 complex\",\n      \"CXCR4/TCR complex\"\n    ],\n    \"partners\": [\n      \"CXCL12\",\n      \"CXCR7\",\n      \"CD74\",\n      \"MIF\",\n      \"ZAP-70\",\n      \"AIP4\",\n      \"GRK6\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}